Ovarian hyperstimulation syndrome- an optimal solution for an unresolved enigma

Journal of Ovarian Research

Raoul Orvieto¹ 

[1] Infertility and IVF Unit, Department of Obstetrics and Gynecology, Sheba Medical Center, Ramat Gan, Israel

关键词: Prevention;    Prediction;    GnRH agonist trigger;    Ovarian stimulation;    Ovarian hyperstimulation syndrome;   

Others  :  805089
DOI  :  10.1186/1757-2215-6-77

 received in 2013-08-23, accepted in 2013-10-29,  发布年份 2013

【 摘 要 】

Ovarian hyperstimulation syndrome (OHSS) is a serious complication of controlled ovarian hyperstimulation (COH). The syndrome almost always presents either after hCG administration in susceptible patients or during early pregnancy. Despite many years of clinical experience, there are no precise methods to completely prevent severe OHSS, except by withholding the ovulation-inducing trigger of hCG. Recently, COH which combining GnRH antagonist co-treatment and GnRH agonist trigger has become a common tool aiming to eliminate severe early OHSS. However, the observed decrease in implantation and pregnancy rates following this approach has encouraged different modifications of luteal support aiming to improve outcome. One of the suggest approach is the 1500 IU hCG luteal rescue, which appears to be a promising protocol, aiming to reduce (rather than eliminating) severe early OHSS, without compromising outcome. In the present paper we discuss the different suggested strategies and offer a strict triage, aimed at eliminating the occurrence of severe OHSS based on several clinical observations, including the role of GnRH-antagonist in COH protocols, the use of different luteal rescue protocols and the ability to transfer embryos in the blastocyst stage.

【 授权许可】

   
2013 Orvieto; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Navot D, Bergh PA, Laufer N: Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992, 58:249-261.
• [2]Orvieto R, Ben-Rafael Z: Ovarian hyperstimulation syndrome: a new insight into an old enigma. J Soc Gynecol Invest 1998, 5:110-113.
• [3]Kol S: Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril 2004, 81:1-5.
• [4]Orvieto R: Can we eliminate severe ovarian hyperstimulation syndrome? Hum Reprod 2005, 20:320-322.
• [5]Devroey P, Polyzos NP, Blockeel C: An OHSS-Free Clinic by segmentation of IVF treatment. Hum Reprod 2011, 6:2593-2597.
• [6]Griesinger G, Diedrich K, Devroey P, Kolibianakis EM: GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update 2006, 12:159-168.
• [7]Orvieto R, Rabinson J, Meltzer S, Zohav E, Anteby E, Homburg R: Substituting HCG with GnRH agonist to trigger final follicular maturation–a retrospective comparison of three different ovarian stimulation protocols. Reprod Biomed Online 2006, 13:198-201.
• [8]Kol S, Humaidan P: GnRH agonist triggering: recent developments. Reprod Biomed Online 2013, 26:226-230.
• [9]Griesinger G, Schultz L, Bauer T, Broessner A, Frambach T, Kissler S: Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a 'freeze-all’ strategy: a prospective multicentric study. Fertil Steril 2011, 95:2029-2033.
• [10]Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C: The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomised controlled study. Fertil Steril 2008, 89:84-91.
• [11]Orvieto R: Intensive luteal-phase support with oestradiol and progesterone after GnRH-agonist triggering: does it help? Reprod Biomed Online 2012, 24:680-681.
• [12]Humaidan P, Bredkjaer HE, Westergaard LG, Andersen CY: 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin- releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril 2010, 93:847-854.
• [13]Humaidan P, Papanikolaou EG, Kyrou D, Alsbjerg B, Polyzos NP, Devroey P, Fatemi HM: The luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives. Reprod Biomed Online 2012, 24:134-141.
• [14]Seyhan A, Ata B, Polat M, Son WY, Yarali H, Dahan MH: Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. Hum Reprod 2013, 28(9):2522-2528.
• [15]Navot D, Bergh PA, Laufer N: The ovarian hyperstimulation syndrome. In Reproductive Endocrinology, Surgery, and Technology. Edited by Adashi E, Rock JA, Rosenwaks Z. Philadelphia: Lippincott–Raven Publishers; 1996:2215-2232.
• [16]Asch RH, Lo HP, Balmaceda JP, Weckstein LN, Stone SC: Severe ovarian hyperstimulation syndrome in assisted reproductive technology: defnition of high risk groups. Hum Reprod 1991, 6:1395-1399.
• [17]Papanikolaou EG, Pozzobon C, Kolibianakis EM, Camus M, Tournaye H, Fatemi HM, Van Steirteghem A, Devroey P: Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 2006, 85:112-120.
• [18]Orvieto R, Ben-Rafael Z: Role of intravenous albumin in the prevention of severe ovarian hyperstimulation syndrome. Hum Reprod 1998, 13:3306-3309.
• [19]Orvieto R, Achiron A, Ben-Rafael Z, Hagay Z, Achiron R: The possible role of intravenous immunoglobulin in preventing preeclampsia. Med Hypoth 1993, 41:160-164.
• [20]Levy T, Orvieto R, Homburg R, Dekel A, Peleg D, Ben-Rafael Z: Severe ovarian hyperstimulation syndrome despite low plasma estrogen levels in a hypogonadotropic hypogonadal patient. Hum Reprod 1996, 11:1177-1179.
• [21]Orvieto R: Elimination of ovarian hyperstimulatin syndrome. Fertil Steril 2012, 97:e29.
• [22]Orvieto R: Prediction of OHSS—challenging the estradiol mitos. Hum Reprod 2003, 18:665-667.
• [23]The Practice Committee of the American Society for Reproductive Medicine (ASRM): Ovarian hyperstimulation syndrome. Fertil Steril 2008, 90:S188-S193.
• [24]Soares SR: Etiology of OHSS and use of dopamine agonists. Fertil Steril 2012, 97:517-522.